Literature DB >> 23261580

Transdermal delivery of imipramine and doxepin from newly oil-in-water nanoemulsions for an analgesic and anti-allodynic activity: development, characterization and in vivo evaluation.

A Gimeno Sandig1, A C Calpena Campmany, F Fernández Campos, M J Martín Villena, B Clares Naveros.   

Abstract

Antidepressants have been considered by their analgesic activity in numerous studies, and specifically tricyclic antidepressants to possess the greatest efficacy. Imipramine and doxepin have been reported to exhibit local anaesthetic properties. In order to investigate their cutaneous analgesic effect after topical application a nanoemulsion vehicle was developed. This nanoemulsion is composed of propilenglicol, Transcutol, water, Labrasol, Plurol Oleique, isostearyl isostearate, oleic acid, and d-limonene. The final concentration of imipramine or doxepin in the nanoemulsion system was 3% (w/w). The nanoemulsions were characterized by pH, viscosity, droplet size, polydispersity index and finally, a morphological and structural examination was carried out by using transmission electron microscopy. Furthermore, the present work also reports stability studies on the nanoemulsion formulations to evaluate the integrity of the formulation; these indicate that formulations are stable for a period of three months. Moreover ex vivo studies were performed to evaluate permeation behaviour through human skin and predict plasma concentrations concluding that topically applied imipramine and doxepin loaded nanoemulsions were safe for a local effect. Similarly, the in vivo analgesic and anti-allodynic activity in rats was evaluated being stronger for the doxepin loaded nanoemulsion. This study demonstrated that nanoemulsion containing doxepin could be promising as an alternative analgesic therapy with a potential clinical application.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23261580     DOI: 10.1016/j.colsurfb.2012.10.061

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  6 in total

Review 1.  Beneath the Skin: A Review of Current Trends and Future Prospects of Transdermal Drug Delivery Systems.

Authors:  Ahlam Zaid Alkilani; Jehad Nasereddin; Rania Hamed; Sukaina Nimrawi; Ghaid Hussein; Hadeel Abo-Zour; Ryan F Donnelly
Journal:  Pharmaceutics       Date:  2022-05-28       Impact factor: 6.525

2.  Protective effects of doxepin cream on radiation dermatitis in breast cancer: A single arm double-blind randomized clinical trial.

Authors:  Laleh Shariati; Alireza Amouheidari; Hajar Naji Esfahani; Alireza Abed; Shaghayegh Haghjooy Javanmard; Ismail Laher; Ahmad Ghasemi; Golnaz Vaseghi
Journal:  Br J Clin Pharmacol       Date:  2020-02-25       Impact factor: 4.335

Review 3.  Transdermal and Topical Drug Administration in the Treatment of Pain.

Authors:  Wojciech Leppert; Malgorzata Malec-Milewska; Renata Zajaczkowska; Jerzy Wordliczek
Journal:  Molecules       Date:  2018-03-17       Impact factor: 4.411

4.  Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation.

Authors:  Paulo Sarango-Granda; Marcelle Silva-Abreu; Ana Cristina Calpena; Lyda Halbaut; María-José Fábrega; María J Rodríguez-Lagunas; Natalia Díaz-Garrido; Josefa Badia; Lupe Carolina Espinoza
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-21

Review 5.  Topical Administration of Terpenes Encapsulated in Nanostructured Lipid-Based Systems.

Authors:  Elwira Lasoń
Journal:  Molecules       Date:  2020-12-07       Impact factor: 4.411

6.  Enrichment of Eucalyptus oil nanoemulsion by micellar nanotechnology: transdermal analgesic activity using hot plate test in rats' assay.

Authors:  Zarith Asyikin Abdul Aziz; Hasmida Mohd Nasir; Akil Ahmad; Siti Hamidah Mohd Setapar; Hafandi Ahmad; Mohd Hezmee Mohd Noor; Mohd Rafatullah; Asma Khatoon; Mohd Adnan Kausar; Irfan Ahmad; Shahida Khan; Majed Al-Shaeri; Ghulam Md Ashraf
Journal:  Sci Rep       Date:  2019-09-23       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.